Product Information
EMTRICITABINE 200 MG CAPSULE is a generic product labeled by Aurobindo Pharma Limited, priced at $12.6867 per EA under NDC 65862030130. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Mar 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
65862030130
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMTRICITABINEApproval Type
Generic (ANDA)
FDA Application
ANDA079188FDA Approved
3/15/2023
TE Code
AB
On Market Since
3/15/2023
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE 200 MG CAPSULE has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 13.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.6867 per EA |
|---|---|
| All-time high | $14.7020 (Aug 14, 2024) |
| All-time low | $12.2497 (Jun 17, 2026) |
| 52-week high | $14.5100 |
| 52-week low | $12.2497 |
| Median price | $14.1121 |
| Average price | $13.9516 |
| Largest weekly change | -14.4% (May 20, 2026) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Emtricitabine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Emtricitabine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EMTRICITABINE 200 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE 200 MG CAPSULE, manufactured by Aurobindo Pharma Limited, is $12.6867 per EA (NDC 65862030130), effective Sep 30, 2026.
How has the price of EMTRICITABINE 200 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE 200 MG CAPSULE has declined 13.7%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE 200 MG CAPSULE?
Since Apr 17, 2024, the NADAC for EMTRICITABINE 200 MG CAPSULE has ranged from a low of $12.2497 (Jun 17, 2026) to a high of $14.7020 (Aug 14, 2024), with a median of $14.1121 per EA.
Are there cheaper alternatives to EMTRICITABINE 200 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of EMTRICITABINE 200 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EMTRICITABINE 200 MG CAPSULE?
EMTRICITABINE 200 MG CAPSULE (NDC 65862030130) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.